Search by Drug Name or NDC
NDC 00187-0653-01 Duobrii .1; .45 mg/g; mg/g Details
Duobrii .1; .45 mg/g; mg/g
Duobrii is a TOPICAL LOTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bausch Health US, LLC. The primary component is HALOBETASOL PROPIONATE; TAZAROTENE.
MedlinePlus Drug Summary
Halobetasol topical is used to treat redness, swelling, itching, and discomfort of various skin conditions in adults and children 12 years of age and older, including plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Halobetasol is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Related Packages: 00187-0653-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Halobetasol Topical
Tazarotene (Tazorac, Fabior) is used to treat acne. Tazarotene (Tazorac) is also used to treat psoriasis (a skin disease in which red, scaly patches form on some areas of the body). Tazarotene (Avage) is used to reduce facial wrinkling and discoloration in patients who are also using other skin care and sunlight avoidance programs. Tazarotene is in a class of medications called retinoids. It works to treat acne and psoriasis by slowing skin cell overgrowth and decreasing skin cell inflammation, which can lead to acne or psoriasis. It works to reduce facial wrinkles and discoloration by causing an increase in the thickness of the outer skin layers.
Related Packages: 00187-0653-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Tazarotene Topical
Product Information
| NDC | 00187-0653 |
|---|---|
| Product ID | 0187-0653_dbee276a-6a2e-4565-a106-09a5bcca8778 |
| Associated GPIs | 90559902484120 |
| GCN Sequence Number | 079688 |
| GCN Sequence Number Description | halobetasol propion/tazarotene LOTION 0.01-0.045 TOPICAL |
| HIC3 | L5F |
| HIC3 Description | ANTIPSORIATICS AGENTS |
| GCN | 46233 |
| HICL Sequence Number | 045706 |
| HICL Sequence Number Description | HALOBETASOL PROPIONATE/TAZAROTENE |
| Brand/Generic | Brand |
| Proprietary Name | Duobrii |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | halobetasol propionate and tazarotene |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | LOTION |
| Route | TOPICAL |
| Active Ingredient Strength | .1; .45 |
| Active Ingredient Units | mg/g; mg/g |
| Substance Name | HALOBETASOL PROPIONATE; TAZAROTENE |
| Labeler Name | Bausch Health US, LLC |
| Pharmaceutical Class | Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Retinoid [EPC], Retinoids [CS] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA209354 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00187-0653-01 (00187065301)
| NDC Package Code | 0187-0653-01 |
|---|---|
| Billing NDC | 00187065301 |
| Package | 1 TUBE in 1 CARTON (0187-0653-01) / 100 g in 1 TUBE |
| Marketing Start Date | 2019-04-25 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 9.99849 |
| Pricing Unit | GM |
| Effective Date | 2024-01-01 |
| NDC Description | DUOBRII 0.01%-0.045% LOTION |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |